| Factor Information | |
|---|---|
| Data ID | 1812 |
| Factor | PVRi (dyne s cm) |
| Description | Increased pulmonary vascular resistance and pulmonary vascular resistance index were observed in CHD patients with severe PAH compared to CHD patients without PAH (P<0.001). |
| Biomarker | NA |
| Classification | E10 (physiological factor - other) |
| Association | |
|---|---|
| Application | diagnosis |
| Objective | we investigated whether ADMA could help specifically identify the disease in a relatively large sample size of CHD patients. |
| p Value | <0.001 |
| Conclusion | Increased pulmonary vascular resistance and pulmonary vascular resistance index were observed in CHD patients with severe PAH compared to CHD patients without PAH (P<0.001). |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 390 |
| CHD Type | isolated CHD |
| CHD Subtype | VSD/ASD/PDA |
| Reference | |
|---|---|
| PMID | 25737007 |
| Year | 2015 |
| Title | Asymmetric Dimethyl-L-Arginine is a Biomarker for Disease Stage and Follow-Up of Pulmonary Hypertension Associated with Congenital Heart Disease. |
| Sample | ||
|---|---|---|
| Population | PAH-CHD patients | |
| Source | a single-center prospective observational study | |
| Region | Changsha, China | |
| Method | Plasma ADMA levels were measured by enzyme-linked immunosorbent assay. | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | Group A:CHD without PAH(Treatment) | Group C:CHD with severe PAH(Control) |
| Number | 20 | 40 |
| Age | 34.0 ± 12.7 years | 27.5 ± 9.1 years |
| Gender (Male: Female) | 4:16 | 11:29 |
| Marker Level | 2.94 (2.34, 3.91) dyne s cm | 16.10 (10.13, 22.73) dyne s cm |
